Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."

"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."

"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."